<DOC>
	<DOCNO>NCT02411825</DOCNO>
	<brief_summary>Primary Objective : To assess healthy adult male subject : - The tolerability safety 21-day repeat subcutaneous ( SC ) dose SAR425899 include two titration step . - Pharmacokinetic ( PK ) parameter SAR425899 ascend repeat SC dose plasma . - Pharmacodynamic ( PD ) effect fast postprandial plasma glucose , insulin , biomarkers lipid metabolism fibroblast growth factor 21 ( FGF21 ) . To assess overweight obese T2DM mellitus patient : - The tolerability safety 28-day repeat SC dos SAR425899 include 2 titration step . - PK parameter SAR425899 ascend repeat SC dose plasma urine . - PD effect fast postprandial plasma glucose , insulin , C-peptide , incretin panel ( total active ghrelin , total peptide YY [ PYY ] , total active glucagon-like peptide -1 [ GLP-1 ] , glucagon total gastric inhibitory polypeptide-1 [ GIP ] ) , body weight , FGF21 , biomarkers lipid metabolism HbA1c .</brief_summary>
	<brief_title>Multiple Ascending Dose Study Healthy Male Subjects Overweight Obese Male Female Type 2 Diabetes Mellitus ( T2DM ) Patients</brief_title>
	<detailed_description>The total study duration approximately 10-15 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Healthy subject : Males , 18 55 year age , inclusive . Body mass index ( BMI ) 20.0 30.0 kg/m^2 , inclusive ; body weight 50.0 120.0 kg , inclusive . Certified healthy comprehensive clinical assessment ( detailed medical history , complete physical examination ) . Comorbidities high weight ( eg , mild impair glucose tolerance , mild hypertension , mild hyperlipidemia ) permit unless , per investigator , condition hamper participation . Normal vital sign 10 minute rest supine : 95 mmHg &lt; systolic blood pressure ( SBP ) &lt; 150 mmHg . 45 mmHg &lt; diastolic blood pressure ( DBP ) &lt; 100 mmHg . 50 bpm &lt; heart rate ( HR ) &lt; 100 bpm . Standard 12lead electrocardiogram ( ECG ) parameters 10 minute rest supine position within ; 120 m &lt; PR &lt; 220 m , QRS &lt; 120 m , QTc ≤430 m , normal ECG . Normal 24hour Holter electrocardiography screening . Laboratory parameter within normal range ; however serum creatinine , alkaline phosphatase , hepatic enzyme ( aspartate aminotransferase , alanine aminotransferase ) , total bilirubin ( unless subject Gilbert syndrome ) exceed upper laboratory norm ( ULN ) . T2DM patient : Males female , 1870 year age . Body weight 50.0150.0 kg , BMI 28.0 42.0 kg/m^2 . Diagnosis T2DM least 1 year stable metformin prior inclusion ; comorbidities relate T2DM otherwise healthy . Normal vital sign supine : 95 mmHg &lt; SBP &lt; 160 mmHg 45 mmHg &lt; DBP &lt; 100 mmHg 50 bpm &lt; HR &lt; 100 bpm Normal standard 12lead ECG supine position unless abnormality clinically irrelevant . Laboratory parameter normal range unless abnormality clinically irrelevant strongly associate T2DM ; total bilirubin exceed ULN . Fasting plasma glucose ≥90 mg/dL . HbA1c ≥6.5 % ≤8.5 % . Females : Sterilization least 3 month inclusion postmenopausal . Both : Signed write informed consent . Not supervised/confined legal administrative reason . Male subject partner childbearing potential ( include lactate woman ) must use double contraception method . Male subject pregnant partner must use condom 2 month last dosing . Male subject agree donate sperm 2 month last dosing . Not undergoing physical training program/planning change activity ; vegetarian follow special diet . Exclusion criterion : Healthy subject : History clinically relevant disease/signs acute illness . History drug hypersensitivity/allergic disease . Smoking 5 cigarettes/day . Any medication within 14 day inclusion within 5 time elimination/pharmacodynamic halflife medication study ; vaccination within last 28 day , biologics give within 4 month inclusion . T2DM patient : History/presence clinically relevant disease/signs acute illness related patient 's metabolic status . History/presence drug hypersensitivity allergic disease . Smoking 5 cigarette per day . If female , pregnancy/breastfeeding . Any intake medication treatment period within 21 day first dose within 5 time halflife medication , except : metformin , standard antihypertensive treatment , statin , acetyl salicylic acid . Thyroid hormone replacement allow dose stable 3 month prior screen . Individual background therapy , consider necessary patient 's welfare , could discontinue duration study , may give discretion Investigator , stable dose ( possible ) intake unlikely interfere investigational product . Treated sulphonylureas 3 month , proton pump inhibitor 1 week prior dose . Vaccination within last 28 day , biologics within 4 month inclusion . Severe hypoglycemia result seizure/unconsciousness/coma/hospitalization diabetic ketoacidosis last 3 month screen . Persistent hyperglycemia control metformin/diet/exercise . Diabetic neuropathy , retinopathy , nephropathy renal impairment . Hepatic impairment . Unstable hypo hyperthyroidism . Both : Headaches/migraine . Recurrent nausea/vomiting . Blood donation within 1 month inclusion . Symptomatic postural hypotension , irrespective decrease BP , asymptomatic postural hypotension define decrease SBP ≥20 mmHg within 3 minute change supine standing . History/presence drug alcohol abuse . Positive result : hepatitis B surface antigen , antihepatitis C virus antibody , antihuman immunodeficiency virus 1 2 antibody . Any condition affect gastric empty absorption GI tract . Surgically treated obesity , bariatric surgery . Severe dyslipidemia fast triglyceride &gt; 450 mg/dL . History pancreatitis pancreatectomy . Amylase/lipase &gt; 3 ULN . History thyroid cancer genetic condition predisposes thyroid cancer . Elevated basal calcitonin . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>